Document Detail

Effect of tibolone on sexual function in late postmenopausal women.
MedLine Citation:
PMID:  18018469     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Sexual dysfunction may significantly affect quality of life and marital relations in the postmenopausal period. The aim of the study was to assess the effect of tibolone on climacteric symptoms and sexuality in late postmenopausal but still symptomatic women. PATIENTS AND METHODS: A six-month prospective study was conducted of two groups of clinically healthy postmenopausal women: a control group (n = 18; mean age 57.8 +/- 4.1 yrs; menopause at 49.7 +/- 2.5; years of amenorrhea 8.1 +/- 4.0 yrs) and a tibolone group (n = 22; mean age 57 +/- 4.5 yrs; menopause at 47.7 +/- 3.9; years of amenorrhea 9.2 +/- 4.6 yrs), who received 2.5 mg tibolone daily for six months. The Kupperman menopausal index (KI) was calculated for both groups at baseline and at six months. Sexual function was assessed by the Female Sexual Function Index (FSFI) questionnaire at the beginning and at the end of the study. The FSFI comprised five main domains: desire, arousal, lubrication, orgasm and pain. Satisfaction and a total score were also recorded. RESULTS: The results showed that during the observation period KI decreased significantly in the tibolone group (15.7 +/- 9.2 vs 11.3 +/- 6.8, p < 0.001), while in the control group no difference was observed. There was a significant improvement of sexual function in the tibolone group in all domains: desire -- from 2.6 +/- 1.0 to 3.1 +/- 1.0 (p < 0.001); arousal -- from 2.3 +/- 1.8 to 3.4 +/- 1.1 (p < 0.001); lubrication - 2.6 +/- 2.1 and 3.5 +/- 1.4 (p < 0.05). The ability to reach orgasm increased (p < 0.001) and pain and discomfort during and after sexual intercourse significantly decreased (p < 0.01). The overall satisfaction and the total score in the treated group changed favourably in a statistically significant manner, while these parameters did not change in the control group. CONCLUSIONS: Treatment with tibolone had a beneficial effect on the climacteric symptoms and sexual function of late postmenopausal women. Moreover, tibolone seems to have an advantage over conventional hormone replacement therapy (HRT) in improving desire and arousal.
Zdravko A Kamenov; Maria K Todorova; Vladimir G Christov
Related Documents :
17350159 - Is the sexual function compromised in long-term testicular cancer survivors?
8599379 - Effects of ontogeny and sexual dimorphism on scapula morphology in the mountain gorilla...
12150079 - Profiles in the offending process of nonserial sexual murderers.
19433349 - Sexual size dimorphism in caecilian amphibians: analysis, review and directions for fut...
12367569 - Sexual partner preference requires a functional aromatase (cyp19) gene in male mice.
18822309 - Developmental plasticity of human reproductive development: effects of early family env...
12185169 - Age related shift in the primary sites of involvement in cervical spondylotic myelopath...
6267319 - Serum protein concentrations and respiratory tract abnormalities following short-term e...
15554609 - Reliability of self-reports: data from the canadian multi-centre osteoporosis study (ca...
Publication Detail:
Type:  Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Folia medica     Volume:  49     ISSN:  0204-8043     ISO Abbreviation:  Folia Med (Plovdiv)     Publication Date:  2007  
Date Detail:
Created Date:  2007-11-16     Completed Date:  2008-01-08     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  2984761R     Medline TA:  Folia Med (Plovdiv)     Country:  Bulgaria    
Other Details:
Languages:  eng     Pagination:  41-8     Citation Subset:  IM    
Clinic of Endocrinology, Alexandrov's Hospital, Department of Pathophysiology, Medical University, Sofia, Bulgaria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Estrogen Receptor Modulators / therapeutic use*
Estrogen Replacement Therapy
Middle Aged
Norpregnenes / therapeutic use*
Postmenopause* / psychology
Prospective Studies
Sexual Dysfunction, Physiological / drug therapy*,  etiology
Reg. No./Substance:
0/Estrogen Receptor Modulators; 0/Norpregnenes; 5630-53-5/tibolone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of surgical periodontal therapy on serum levels of TNF-alpha in patients with chronic period...
Next Document:  Immunological and microbiological investigations of patients with burn injuries.